Natalia Chernova

Prof. Dr. Natalia Chernova

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
YSYulia Sidorova
Yulia Sidorova
KSKseniya A. Sychevskaya
Kseniya A. Sychevskaya
NCNatalia Chernova
Natalia Chernova
HJHunan Julhakyan
Hunan Julhakyan
SSSvetlana Ju. Smirnova
Svetlana Ju. Smirnova
ASAndrey Sudarikov
Andrey Sudarikov

1 January 2016 in Terapevticheskii arkhiv
Verified
Journal Article
Closed access
ENE. S. Nesterova
E. S. Nesterova
SKS. K. Kravchenko
S. K. Kravchenko
YMYa. K. Mangasarova
Ya. K. Mangasarova
EBE. A. Baryakh
E. A. Baryakh
AMA. E. Misyurina
A. E. Misyurina
TGT. V. Gaponova
T. V. Gaponova
The first prospective study of intensive therapy for FL in Russia has demonstrated that HDCT with further auto-BSCT in first-line therapy allows complete remission in patients with poor prognostic factors and higher overall and progression-free survival rates.

1 January 2014 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
NCNatalia Chernova
Natalia Chernova
ЮВЮ. Е. Виноградова
Ю. Е. Виноградова
ЮСЮ. В. Сидорова
Ю. В. Сидорова
ИКИ. Б. Капланская
И. Б. Капланская
ЕГЕ. А. Гилязитдинова
Е. А. Гилязитдинова
СКС. К. Кравченко
С. К. Кравченко
Introduction: Current СНОР-like therapy for angioimmunoblastic T-cell lymphoma demonstrates unsatisfactory results with respect to the achievement of complete remission. It indicates the need in the search for new approaches to therapy of angioimmunoblastic T-cell lymphoma. Objective: To define the rational approaches to the diagnosis and treatment of angioimmunoblastic T-cell lymphoma (AITL). Materials and methods: Within the period from 2002 to 2012, we followed-up 15 patients with angioimmunoblastic T-cell lymphoma, with median age of 61 years (range 29–77) and the male/female ratio of 11/4. All patients had stage IV disease; the bone marrow, lungs, spleen, and skin were involved in 14 (93 %), 9 (60 %), 12 (80 %), and 6 (40 %) patients, respectively. Results: We used prolonged chemotherapy GMALL 2002 and ALL-2009 regimens for treatment of angioimmunoblastic T-cell lymphoma (11 patients). Complete remission was achieved in 55 % of cases with median follow up of 33 mouths. Conclusion: The usage of short-term chemotherapy programs (CHOP-like) for treatment of angioimmunoblastic T-cell lymphoma doesn’t seem to give good results. Administration of prolonged chemotherapy is more appropriate and allows achieving remission of the disease.

15 July 2017 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
НГН. Г. Габеева
Н. Г. Габеева
ДКД. А. Королева
Д. А. Королева
ABA. V. Belyaeva
A. V. Belyaeva
NCNatalia Chernova
Natalia Chernova
ЛКЛ. А. Кузьмина
Л. А. Кузьмина
ВСВ. Г. Савченко
В. Г. Савченко
Double-hit lymphoma (DHL) is a rare aggressive B-cell lymphoma with concomitant c-MYC, BCL2 or BCL6 gene rearrangements, which is characterized by the high frequency of extranodal lesions and by resistance to chemotherapy. The median survival does not exceed 18 months in patients with this disease. The majority of DHL is represented by с-MYC/BCL2 cases. The combination of c-MYC/BCL6 occurs rarely (5—8%). The paper describes a case of DHL with concomitant c-MYC and BCL6 gene rearrangements, which mimics diffuse large B-cell lymphoma, leg-type.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
EMElena N. Misyurina
Elena N. Misyurina
EZE. N. Zotina
E. N. Zotina
SGS. M. Gadzhieva
S. M. Gadzhieva
NCNatalia Chernova
Natalia Chernova
EKE. A. Karimova
E. A. Karimova
TST. A. Semina
T. A. Semina
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.

15 July 2018 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
NCNatalia Chernova
Natalia Chernova
EZE E Zvonkov
E E Zvonkov
DBD S Badmazhapova
D S Badmazhapova
MSM N Sinitsyna
M N Sinitsyna
LGL A Grebenyuk
L A Grebenyuk
VSV G Savchenko
V G Savchenko
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen. In the article we present a literature review and describe our clinical case of nALCL, ALK-. For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient.